Irregular Menstrual Cycle
Conditions
Keywords
Duphaston Study
Brief summary
In India Duphaston is approved and widely used for the treatment of progesterone deficiencies such as for management of dysmenorrhea, endometriosis, secondary amenorrhea, irregular cycles, dysfunctional uterine bleeding, pre-menstrual syndrome, threatened and habitual abortion, infertility due to luteal insufficiency, as well as part of hormone replacement therapy. One Indian study reported normalization of the cycle in 91.6% of women with menstrual problems after three cycles of therapy with dydrogesterone 10 mg given from 11th to the 25th day of the menstrual cycle. The mean cycle duration during dydrogesterone therapy in this study was noted to be 28.8 days, in contrast to 17.9 days (in the polymenorrhea group) and 50.6 days (in the oligomenorrhea group) before therapy. Furthermore, dydrogesterone also decreased the amount and duration of menstrual bleeding in this study. However, there are limited data regarding Duphaston's role in achieving cycle regularization from post-marketing settings. Moreover, it is not well-known if the effect of Duphaston therapy persists after cessation of treatment and whether the persistent effect, if any, is related to the duration of Duphaston therapy. Hence, in this observational study, given that (based on previous clinical studies as mentioned above) Duphaston plays a role in menstrual irregularities treatment, the goal is to tease out the possible implications of such treatment in terms of treatment length and response pattern.
Detailed description
Primary objective: • To determine percentage of patients reporting a regular cycle (defined as cycle duration between 21 to 35 days, inclusive) at the end of treatment period. Secondary objectives: A. For all patients: * To describe evolution of cycle duration from baseline to end of treatment by assessing mean cycle duration (in days) at baseline, separately in polymenorrhea, (i.e., cycle duration < 21 days) and oligomenorrhea (i.e., cycle duration > 35 days) groups, and at the end of treatment. * To describe evolution of duration of menstrual bleeding from baseline to end of treatment by assessing mean duration of menstrual bleeding (in days) at baseline and at the end of treatment. * To describe evolution of amount of menstrual bleeding from baseline to end of treatment, by assessing average number of pads changed per day at baseline and at the end of treatment. * To describe evolution of pain during menstruation (on a 11 point Likert Scale where 0 means no pain and 10 means worst pain) ) from baseline to end of treatment, by assessing mean and standard deviation of pain scores at baseline and at the end of treatment. * To describe overall patient satisfaction (on a 5 point Clinical Global Impression of Severity scale, where 1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat satisfied, 4 = satisfied, 5 = very satisfied) at the end of treatment, by assessing percentages of patients in each category at the end of treatment. * To describe overall clinical response (on a 7 point Clinical Global Impression of Severity scale, where 1 = Normal, not at all ill, 2 = Borderline mentally ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, 7 = Most extremely ill) ) at the end of treatment by assessing percentages of patients in each category at the end of treatment. B. For patients who had achieved regular cycle at the end of treatment: * To determine the percentage of patients still experiencing regular cycle (i.e., duration 21-35 days, inclusive) at the end of follow up period, out of total number of patients who had achieved cycle regularization at the end of treatment period. * To determine median time to relapse (defined as cycle duration < 21 days or > 35 days) during the follow up period, for patients who had achieved regular cycle at the end of treatment, using Kaplan Meier's method to graphically plot time after cessation of treatment versus percentage of patients still having regular cycles. * To determine any correlation between treatment duration (number of cycles of Duphaston treatment received) and persistence of effect (number of months until when regular cycles are maintained after cessation of Duphaston therapy), using linear regression analysis model. * To describe evolution of duration of menstrual bleeding from cessation of treatment to end follow up, by assessing mean duration of menstrual bleeding (in days) at end of treatment and at the end of follow up. * To describe evolution of amount of menstrual bleeding from cessation of treatment to end follow up, by assessing average number of pads changed per day at end of treatment and at the end of follow up. * To describe evolution of pain during menstruation (on a 11 point Likert Scale where 0 means no pain and 10 means worst pain) from cessation of treatment to end follow up, by assessing mean and standard deviation of pain scores at end of treatment and at the end of follow up.
Interventions
None listed
Sponsors
Abbott
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Women aged 18 years or older * Suffering from irregular menstrual cycle for at least 3 months and for whom the physician decides to prescribe Duphaston, in accordance with locally approved package insert * Patients willing to sign written authorization to provide data for the study
Exclusion criteria
* Patients having known hypersensitivity to the active ingredient or excipients * Patients having known or suspected progesterone-dependent neoplasms * Patients having vaginal bleeding of unknown etiology * Patients taking oral contraceptives * Pregnant and lactating patients * Any other condition that precludes use of Duphaston in a particular patient, in accordance with the contraindication, precautions and special warnings listed in the locally approve package insert (for example, patients with history of liver disease, porphyria or depression) * Patients not willing to sign written authorization for data release consent form
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Patients Reporting a Regular Cycle | 6 months | Regular cycle is defined as cycle duration between 21 to 35 days, inclusive at the end of treatment period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Amount of Menstrual Bleeding From Baseline to End of Treatment | 6 months | Assessment of average number of pads changed per day at baseline and at the end of treatment (EOT). |
| Evolution of Pain During Menstruation From Baseline to End of Treatment | 6 months | The scores for pain during menstruation were recorded on 11-point Likert scale on baseline and end of treatment where 0 means no pain, and 10 means worst pain. |
| Change in Cycle Duration (in Days) From Baseline to End of Treatment (EOT) | 6 months | The evolution of cycle duration from baseline to EOT was assessed by mean cycle duration (in days) at baseline, separately in polymenorrhea and oligomenorrhea groups, and at the EOT. The patients were included in polymenorrhea group in case the cycle duration at baseline was less than 21 days and in oligomenorrhea group in case the cycle duration at baseline was greater than 35 days. |
| Evolution of Duration of Menstrual Bleeding From Baseline to End of Treatment | 6 months | To observe the evolution of duration of menstrual bleeding from baseline to end of treatment by assessing mean duration of menstrual bleeding (in days) at baseline and at the end of treatment. |
| Overall Clinical Response | 6 months | Overall response (on a 7 point Clinical Global Impression of Severity scale, where 1 = Normal, not at all ill, 2 = Borderline ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, 7 = Most extremely ill) at the EOT by assessing percentages of patients in each category at the EOT. |
| Overall Patient Satisfaction | 6 months | The overall patient satisfaction was recorded on a 5 point Clinical Global Impression of Severity scale, where 1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat satisfied, 4 = satisfied, 5 = very satisfied). |
Countries
India
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Subjects With Irregular Menstrual Cycle Adult subjects with irregular menstrual cycle and can be treated with Duphaston as per locally approved label can be enrolled. | 1,000 |
| Total | 1,000 |
Baseline characteristics
| Characteristic | Subjects With Irregular Menstrual Cycle |
|---|---|
| Age, Customized Age | 29.2 years STANDARD_DEVIATION 7.41 |
| Sex/Gender, Customized Female | 1000 participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 3 / 1,000 |
| serious Total, serious adverse events | 1 / 1,000 |
Outcome results
Primary
Percentage of Patients Reporting a Regular Cycle
Regular cycle is defined as cycle duration between 21 to 35 days, inclusive at the end of treatment period.
Time frame: 6 months
Population: Intent-to-Treat Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Subjects With Irregular Menstrual Cycle | Percentage of Patients Reporting a Regular Cycle | 96.7 percentage of participants |
Secondary
Amount of Menstrual Bleeding From Baseline to End of Treatment
Assessment of average number of pads changed per day at baseline and at the end of treatment (EOT).
Time frame: 6 months
Population: The amount of menstrual bleeding (based on no. of pads used per day) was analyzed for all subjects completing EOT and change was noted from baseline to EOT
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Subjects With Irregular Menstrual Cycle | Amount of Menstrual Bleeding From Baseline to End of Treatment | baseline amount of bleeding | 3.08 pads/day | Standard Deviation 1.26 |
| Subjects With Irregular Menstrual Cycle | Amount of Menstrual Bleeding From Baseline to End of Treatment | EOT amount of bleeding | 2.63 pads/day | Standard Deviation 0.89 |
| Subjects With Irregular Menstrual Cycle | Amount of Menstrual Bleeding From Baseline to End of Treatment | Change from baseline to EOT | -0.45 pads/day | Standard Deviation 1.2 |
Secondary
Change in Cycle Duration (in Days) From Baseline to End of Treatment (EOT)
The evolution of cycle duration from baseline to EOT was assessed by mean cycle duration (in days) at baseline, separately in polymenorrhea and oligomenorrhea groups, and at the EOT. The patients were included in polymenorrhea group in case the cycle duration at baseline was less than 21 days and in oligomenorrhea group in case the cycle duration at baseline was greater than 35 days.
Time frame: 6 months
Population: All patients were assessed for overall reduction in cycle duration (910).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Subjects With Irregular Menstrual Cycle | Change in Cycle Duration (in Days) From Baseline to End of Treatment (EOT) | Cycle duration at baseline | 44.73 Days | Standard Deviation 25.38 |
| Subjects With Irregular Menstrual Cycle | Change in Cycle Duration (in Days) From Baseline to End of Treatment (EOT) | Cycle duration at EOT | 28.59 Days | Standard Deviation 7.61 |
| Subjects With Irregular Menstrual Cycle | Change in Cycle Duration (in Days) From Baseline to End of Treatment (EOT) | change from baseline to EOT | -16.14 Days | Standard Deviation 24.04 |
Secondary
Evolution of Duration of Menstrual Bleeding From Baseline to End of Treatment
To observe the evolution of duration of menstrual bleeding from baseline to end of treatment by assessing mean duration of menstrual bleeding (in days) at baseline and at the end of treatment.
Time frame: 6 months
Population: To observe the evolution of duration of menstrual bleeding from baseline (all enrolled) to end of treatment by assessing mean duration of menstrual bleeding (in days) at baseline and at the end of treatment (EOT).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Subjects With Irregular Menstrual Cycle | Evolution of Duration of Menstrual Bleeding From Baseline to End of Treatment | duration of menstrual bleeding at baseline (days) | 4.99 Days | Standard Deviation 3.15 |
| Subjects With Irregular Menstrual Cycle | Evolution of Duration of Menstrual Bleeding From Baseline to End of Treatment | duration of menstrual bleeding at EOT (days) | 4.29 Days | Standard Deviation 1.38 |
Secondary
Evolution of Pain During Menstruation From Baseline to End of Treatment
The scores for pain during menstruation were recorded on 11-point Likert scale on baseline and end of treatment where 0 means no pain, and 10 means worst pain.
Time frame: 6 months
Population: The scores for pain during menstruation were recorded on 11-point Likert scale on baseline for all enrolled subjects and end of treatment where 0 means no pain, and 10 means worst pain.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Subjects With Irregular Menstrual Cycle | Evolution of Pain During Menstruation From Baseline to End of Treatment | No. of participants at Baseline (Scale 0-No Pain) | 139 participants |
| Subjects With Irregular Menstrual Cycle | Evolution of Pain During Menstruation From Baseline to End of Treatment | No. of participants EOT (Scale 0-No Pain) | 200 participants |
| Subjects With Irregular Menstrual Cycle | Evolution of Pain During Menstruation From Baseline to End of Treatment | No. of participants Baseline (Scale 10-Worst Pain) | 5 participants |
| Subjects With Irregular Menstrual Cycle | Evolution of Pain During Menstruation From Baseline to End of Treatment | No. of participants EOT (Scale 10-Worst Pain) | 0 participants |
Secondary
Overall Clinical Response
Overall response (on a 7 point Clinical Global Impression of Severity scale, where 1 = Normal, not at all ill, 2 = Borderline ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, 7 = Most extremely ill) at the EOT by assessing percentages of patients in each category at the EOT.
Time frame: 6 months
Population: Overall response (on a 7 point Clinical Global Impression of Severity scale, where 1 = Normal, not at all ill, 2 = Borderline ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, 7 = Most extremely ill) at the EOT by assessing percentages of patients in each category at the EOT.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Subjects With Irregular Menstrual Cycle | Overall Clinical Response | Overall Clinical Response EOT(Most extremely ill) | 0 participants |
| Subjects With Irregular Menstrual Cycle | Overall Clinical Response | Overall Clinical Response EOT (Normal, not ill) | 851 participants |
Secondary
Overall Patient Satisfaction
The overall patient satisfaction was recorded on a 5 point Clinical Global Impression of Severity scale, where 1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat satisfied, 4 = satisfied, 5 = very satisfied).
Time frame: 6 months
Population: Overall at the EOT, of 910 patients population the overall satisfaction was assessed
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Subjects With Irregular Menstrual Cycle | Overall Patient Satisfaction | EOT - Patient satisfaction (very satisfied - 5) | 282 participants |
| Subjects With Irregular Menstrual Cycle | Overall Patient Satisfaction | EOT - Patient satisfaction (satisfied - 4) | 532 participants |